Top Page
China Medical System Holdings
(0867)
China Medical System Holdings (0867) vs. iShares MSCI Hong Kong ETF (EWH)
China Medical System Holdings Business Overview & Revenue Model
China Medical System Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.86B | 7.47B | 8.01B | 9.15B | 8.34B | 6.95B |
| Gross Profit | 5.62B | 5.42B | 6.11B | 7.04B | 6.25B | 5.13B |
| EBITDA | 2.30B | 2.31B | 2.92B | 3.76B | 3.70B | 3.05B |
| Net Income | 1.65B | 1.62B | 2.40B | 3.26B | 3.02B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 18.94B | 18.05B | 17.73B | 17.75B | 15.81B | 12.70B |
| Cash, Cash Equivalents and Short-Term Investments | 5.97B | 5.87B | 6.14B | 5.87B | 4.36B | 2.67B |
| Total Debt | 747.60M | 860.74M | 1.30B | 1.81B | 1.71B | 600.16M |
| Total Liabilities | 1.77B | 1.64B | 2.17B | 3.02B | 2.96B | 1.60B |
| Stockholders Equity | 17.02B | 16.31B | 15.52B | 14.59B | 12.75B | 11.03B |
Cash Flow | ||||||
| Free Cash Flow | 493.64M | 812.64M | 2.18B | 3.03B | 2.31B | 2.35B |
| Operating Cash Flow | 952.52M | 1.27B | 2.50B | 3.55B | 2.49B | 2.69B |
| Investing Cash Flow | -439.01M | -615.10M | -442.28M | -1.18B | -1.52B | -353.82M |
| Financing Cash Flow | -983.08M | -1.26B | -2.13B | -1.40B | -258.39M | -1.03B |
China Medical System Holdings Technical Analysis
China Medical System Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $44.96B | 9.63 | 7.86% | 6.92% | 1.13% | -13.53% | |
74 Outperform | $33.45B | 12.13 | 14.91% | 3.76% | -0.45% | 9.00% | |
73 Outperform | HK$31.09B | 14.75 | 12.65% | 2.97% | 10.56% | -13.58% | |
68 Neutral | HK$31.10B | 10.23 | 5.90% | 2.75% | ― | ― | |
65 Neutral | $33.79B | 18.88 | 10.01% | 2.12% | 11.78% | 19.06% | |
65 Neutral | $24.88B | 6.94 | 21.02% | 4.93% | 0.39% | 4.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
China Medical System Holdings Corporate Events
China Medical System Holdings has announced that its subsidiary, Dermavon Holdings, has had its new drug application for MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, accepted by China’s National Medical Products Administration. This drug, intended for treating moderate-to-severe atopic dermatitis, has shown promising results in clinical trials and is expected to enhance patient adherence due to its four-week dosing schedule. If approved, MG-K10 will enrich the company’s dermatological product portfolio and strengthen Dermavon’s market competitiveness.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has entered into a Distribution Agreement with Novartis Pharma Services AG for the exclusive rights to distribute Lucentis® and Beovu® in mainland China. This agreement enhances the company’s portfolio in the ophthalmic drug market, allowing it to capitalize on the growing demand for anti-VEGF drugs in China, projected to expand significantly by 2030. The inclusion of Lucentis®, a well-established treatment for ocular neovascular diseases, and Beovu®, a novel treatment for diabetic macular edema, strengthens the company’s position in the ophthalmic sector and offers potential growth opportunities.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced that its innovative drug, MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody, has received approval from the National Medical Products Administration to conduct clinical trials for treating Chronic Obstructive Pulmonary Disease (COPD). This development positions MG-K10 as a potential Best-in-Class treatment with a four-week dosing frequency, which could significantly impact the market by offering a longer-lasting alternative to current biweekly anti-IL-4Rα treatments.
China Medical System Holdings Limited has reported no changes in its authorized share capital for the month ending September 2025, maintaining a total of 20 billion ordinary shares with a par value of USD 0.005, amounting to a total authorized share capital of USD 100 million. This stability in share capital indicates a steady financial position for the company, which could reassure stakeholders and investors about its current market standing.
China Medical System Holdings announced that its subsidiary, Dermavon Holdings, received approval from the National Medical Products Administration to conduct Phase III clinical trials for MG-K10, a long-acting anti-IL-4Rα monoclonal antibody, for treating chronic spontaneous urticaria (CSU). This development positions MG-K10 as a potential best-in-class treatment option, enhancing the company’s product portfolio and offering new therapeutic options for patients in China. The approval is expected to strengthen the company’s market position and provide a synergistic effect with its existing dermatological products.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced that its innovative drug, CMS-D002, has received approval from the National Medical Products Administration for clinical trials targeting uterine fibroids. This approval marks a significant step in expanding the drug’s indications beyond endometriosis, potentially enhancing the company’s product portfolio and strengthening its position in the gynecological treatment market. CMS-D002, a GnRH receptor antagonist, offers a promising treatment option without the flare-up effect seen in other treatments, potentially meeting the unmet clinical demand for effective and safe uterine fibroid therapies.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced positive results from a Phase 3 clinical trial of ruxolitinib cream for treating mild to moderate atopic dermatitis in Chinese patients. The trial demonstrated significant efficacy and safety, with a higher proportion of patients achieving improvement compared to placebo. The company is advancing the new drug application process in China, potentially impacting the treatment landscape for atopic dermatitis, a condition affecting millions in the country.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has entered into exclusive collaboration agreements with Chongqing Genrix Biopharmaceutical Co., Ltd. for two innovative biologic products: Vecantoxatug Injection, aimed at passive immunization against tetanus, and Silevimig Injection, targeting rabies virus exposure. These agreements grant the company commercialization rights in mainland China and licensing rights across the Asia-Pacific, Middle East, and North Africa regions. The collaboration enhances the company’s portfolio in passive immunization, potentially offering advanced therapeutic options with improved safety and accessibility, thus strengthening its market position in the biopharmaceutical sector.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$15.60 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced the transition to electronic dissemination of its corporate communications, replacing printed versions with digital ones accessible via their website and other financial news platforms. This shift aims to streamline communication with shareholders and ensure timely access to important documents, potentially enhancing operational efficiency and aligning with modern digital practices.
China Medical System Holdings Limited has announced the adoption of electronic dissemination for its corporate communications. This move is aimed at improving accessibility and efficiency for shareholders, allowing them to access important documents such as directors’ reports, financial accounts, and meeting notices online. This transition to digital communication is expected to streamline operations and enhance stakeholder engagement.
China Medical System Holdings Limited reported no changes in its authorized share capital for August 2025, maintaining a total of 20 billion ordinary shares with a par value of USD 0.005 each, amounting to an authorized share capital of USD 100 million. This stability in share capital suggests a steady financial strategy, potentially reassuring stakeholders about the company’s consistent market positioning and operational focus.
China Medical System Holdings announced that its subsidiary, Dermavon Holdings, received approval from China’s National Medical Products Administration to conduct clinical trials for the drug Povorctinib, targeting non-segmental vitiligo and moderate to severe hidradenitis suppurativa. This approval marks a significant step in the company’s expansion in the dermatological treatment market, potentially enhancing its industry positioning and offering new opportunities for stakeholders.
China Medical System Holdings Limited announced a 10.8% increase in turnover and a 3.1% rise in profit for the first half of 2025, driven by the growth of major exclusive and branded products. The company achieved a significant milestone by completing its secondary listing on the SGX-ST, enhancing its brand influence and establishing an integrated ecosystem to capture growth potential in emerging markets.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited announced an interim cash dividend of RMB 0.1555 per share for the six months ending June 30, 2025. The dividend, payable in Hong Kong dollars at HKD 0.171 per share, reflects the company’s ongoing commitment to delivering shareholder value. The ex-dividend date is set for August 29, 2025, with payment scheduled for September 9, 2025. This announcement underscores the company’s stable financial performance and its strategic focus on maintaining investor confidence.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced the composition of its board of directors, which includes executive directors Mr. Lam Kong and Ms. Chen Yanling, and independent non-executive directors Mr. Leung Chong Shun, Ms. Luo Laura Ying, and Mr. Fung Ching Simon. The board has also established four committees, each with designated members, to enhance governance and operational oversight, reflecting the company’s commitment to structured leadership and strategic management.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited has announced a Board meeting scheduled for August 18, 2025, to discuss and approve the interim results for the six months ended June 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
China Medical System Holdings Limited reported no changes in its authorized or registered share capital for July 2025, maintaining a total of 20 billion ordinary shares with a par value of USD 0.005 each, amounting to a total share capital of USD 100 million. This stability in share capital indicates a steady financial position, potentially reassuring stakeholders and investors about the company’s consistent market presence.
The most recent analyst rating on (HK:0867) stock is a Buy with a HK$14.33 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.